Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Axil Capital is a venture capital firm located in Tokyo, Japan, that specializes in biomedical and healthcare technology investments. Founded in 2017 as a spin-off from Mizuho Securities, the firm has established itself as a key player in the life sciences sector. Axil Capital aims to create synergies between Japan's biotechnology ecosystem and global markets, focusing on building companies that deliver long-term value and sustainable returns to investors.
As of now, Axil Capital manages a diverse portfolio and has made significant strides in the life sciences sector. The firm invests across various stages, from pre-seed to growth equity, allowing it to support startups at different points in their development. The firm operates from two main offices in Tokyo, enhancing its ability to connect with local and international biotech communities.
Axil Capital's investment strategy centers on the life sciences sector, with a particular emphasis on biopharmaceuticals, medical devices, digital health, and healthcare services. The firm targets a wide range of investment stages, including pre-seed, seed, Series A, Series B, Series C, and growth equity. This broad approach allows Axil Capital to diversify its portfolio and adapt to the evolving needs of the healthcare market.
In its investment decisions, Axil Capital seeks to identify innovative companies that demonstrate potential for significant growth and impact in the healthcare technology space. The firm values founders who are committed to advancing healthcare solutions and improving patient outcomes. By investing in both early-stage ventures and late-stage crossover rounds, Axil Capital aims to foster innovation and drive sustainable growth in the life sciences sector.
Axil Capital has built a notable portfolio of companies within the life sciences sector. Key investments include:
This diverse portfolio reflects Axil Capital's commitment to supporting innovative companies that are making significant contributions to healthcare technology and life sciences.
Frederick Schoen - Managing Partner: Frederick has extensive experience in venture capital and healthcare investments, having previously worked at Mizuho Securities.
Hiroshi Utsunomiya - Partner: Hiroshi brings a wealth of knowledge in the life sciences sector, focusing on strategic investments and partnerships.
Yoshitake Maeda - Venture Partner: Yoshitake has a strong background in biotechnology and has led several successful investments in the field.
Kaito Usui, Ph.D. - Senior Principal: Kaito specializes in biomedical technology and has a Ph.D. in a relevant scientific discipline.
Jun Baek, Ph.D., MBA - Principal: Jun combines his scientific expertise with business acumen, focusing on investment opportunities in healthcare.
Kenji Maekubo, M.S. - Principal: Kenji has a Master's degree in a relevant field and focuses on operational aspects of portfolio companies.
Akio Kiyota, Ph.D. - Principal: Akio's background in research and development in life sciences informs his investment decisions.
What are Axil Capital's investment criteria?
Axil Capital focuses on the life sciences sector, targeting companies involved in biopharmaceuticals, medical devices, digital health, and healthcare services. The firm invests across various stages, from pre-seed to growth equity, and looks for innovative solutions that can significantly impact healthcare.
How can founders pitch to Axil Capital?
Founders can pitch to Axil Capital by submitting a detailed business plan that outlines their product, market potential, and team. A clear demonstration of innovation and potential for growth is essential.
What makes Axil Capital different from other VC firms?
Axil Capital's strong focus on the life sciences sector and its commitment to fostering innovation in healthcare technology set it apart. The firm actively seeks to create synergies between Japan's biotechnology ecosystem and global markets.
What is the geographic focus of Axil Capital?
Axil Capital primarily focuses on investments in Asia, particularly Japan, while also considering opportunities that have global implications in the life sciences sector.
What is Axil Capital's approach to post-investment involvement?
Axil Capital takes an active role in supporting its portfolio companies, providing mentorship, operational support, and access to its network to help them grow and succeed in the competitive healthcare market.
What is the typical check size for investments made by Axil Capital?
While specific check sizes can vary, Axil Capital invests across a range of stages, which typically includes early-stage investments as well as larger amounts for later-stage rounds, reflecting their commitment to supporting companies at different growth phases.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.